BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 12170084)

  • 21. [Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein, CD34 and CD10 in hepatocellular carcinoma: a clinicopathologic analysis of 375 cases].
    Du JL; Wang YL; Shi HY; Guo AT; Wei LX
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):309-13. PubMed ID: 22883669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel diagnostic marker, p28GANK distinguishes hepatocellular carcinoma from potential mimics.
    Fu X; Tan L; Liu S; Li H; Chen L; Qin J; Wu M; Wang H
    J Cancer Res Clin Oncol; 2004 Sep; 130(9):514-20. PubMed ID: 15221469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.
    Ramos-Vara JA; Miller MA; Johnson GC
    Vet Pathol; 2001 Nov; 38(6):636-43. PubMed ID: 11732796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
    Hanif R; Mansoor S
    J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.
    Mondada D; Bosman FT; Fontolliet C; Seelentag WK
    Virchows Arch; 2006 Jan; 448(1):35-45. PubMed ID: 16220294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic utility of CD10 immunohistochemical staining on cellblock in differentiating hepatocellular carcinoma from secondary malignancies of liver.
    Singha J; Khan K; Chatterjee S
    Indian J Pathol Microbiol; 2018; 61(4):510-515. PubMed ID: 30303139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hep Par 1 in gastric and bowel carcinomas: an immunohistochemical study.
    Villari D; Caruso R; Grosso M; Vitarelli E; Righi M; Barresi G
    Pathology; 2002 Oct; 34(5):423-6. PubMed ID: 12408340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histologic markers in primary and metastatic tumors of the liver.
    Ganjei P; Nadji M; Albores-Saavedra J; Morales AR
    Cancer; 1988 Nov; 62(9):1994-8. PubMed ID: 2458825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. pCEA canalicular immunostaining in fine needle aspiration biopsy diagnosis of hepatocellular carcinoma.
    Wee A; Nilsson B
    Acta Cytol; 1997; 41(4):1147-55. PubMed ID: 9250313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of alpha-fetoprotein and immunoreactive carcinoembryonic antigen in human hepatocellular carcinoma and hepatoblastoma.
    Hirohashi S; Shimosato Y; Ino Y; Kishi K; Ohkura H; Mukojima T
    Jpn J Clin Oncol; 1983 Mar; 13(1):37-43. PubMed ID: 6187946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic hepatocellular carcinoma of skin diagnosed with hepatocyte paraffin 1 and a-fetoprotein immunostainings.
    Terada T; Sugiura M
    Int J Surg Pathol; 2010 Oct; 18(5):433-6. PubMed ID: 18499685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples.
    Lugli A; Tornillo L; Mirlacher M; Bundi M; Sauter G; Terracciano LM
    Am J Clin Pathol; 2004 Nov; 122(5):721-7. PubMed ID: 15491968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
    Li J; Wei L
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
    Pour AM; Masir N; Rose IM
    Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples.
    Siddiqui MT; Saboorian MH; Gokaslan ST; Ashfaq R
    Cancer; 2002 Feb; 96(1):49-52. PubMed ID: 11836703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas.
    Borscheri N; Roessner A; Röcken C
    Am J Surg Pathol; 2001 Oct; 25(10):1297-303. PubMed ID: 11688465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [An immunohistochemical study on primary carcinoma of the liver].
    Seo JK
    J UOEH; 1989 Dec; 11(4):429-39. PubMed ID: 2481871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
    DU JL; Wei LX; Wang YL
    Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers.
    Porcell AI; De Young BR; Proca DM; Frankel WL
    Mod Pathol; 2000 Jul; 13(7):773-8. PubMed ID: 10912937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen.
    Fasano M; Theise ND; Nalesnik M; Goswami S; Garcia de Davila MT; Finegold MJ; Greco MA
    Mod Pathol; 1998 Oct; 11(10):934-8. PubMed ID: 9796718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.